HDAC9 and ovarian carcinoma: These SMs were combined with different HDAC inhibitors, including the class I selective HDAC inhibitor, entinostat, reported to have an anti-tumor effect in an ovarian cancer model [15], the broader-acting panobinostat, as well as romidepsin and vorinostat.